

주최·주관 대한심장혈관흉부외과학회

# 2024 대한심장혈관흉부외과학회 제56차 추계학술대회

2024. 10. 31 (Thu) - 11. 01 (Fri) 여수 엑스포 컨벤션센터




## The mid-term outcomes of Neo-chordae folding plasty technique in minimally invasive mitral valve plasty

- Our center has been performing neo-chorda folding plasty (NCFP) technique for mitral valve repair surgery since 2013.
- The purpose of this study is to investigate the mid-term outcomes of NCFP in mitral valve repair via minimally invasive approach following a review of our 10-year experience.

# Methods

- Between December 2008 and June 2024, 487 mitral valve repair were performed using minimally invasive approach via right anterolateral thoracotomy.
- We compared the perioperative results to evaluate the durability of NCFP depending on whether NCFP was performed.



# Results : Demographic data

2024 대한심장혈관흉부외과학회  
제56차 추계학술대회





	No folding plasty	Folding plasty	P-value
	(N=285, 58.5%)	(N=202, 41.5%)	
Female	128 (44.9%)	74 (36.6%)	0.083
Age	56.3 ± 15.4	59.4 ± 14.0	0.021
Hypertension	155 (54.4%)	136 (67.3%)	0.006
Diabetes	48 (16.8%)	23 (11.4%)	0.220
Stroke	32 (11.3%)	24 (11.9%)	0.959
NYHA 3 or 4	128 (44.9%)	112 (55.4%)	0.028
Emergent operation	11 (3.9%)	1 (0.5%)	0.039
Euro Score II (%)	2.2 [ 1.2; 4.4]	1.6 [ 0.9; 4.1]	0.011
Ejection fraction (%)	62.5 ± 9.4	63.5 ± 8.6	0.254
MR Gr ≥ 3	<b>247 (87.3%)</b>	<b>202 (100.0%)</b>	<b>&lt; 0.001</b>

# Results: perioperative data

	No NCFP	NCFP	P-value
	(N=285)	(N=202)	
Annuloplasty ring size (mm)	29.6 ± 2.7	29.1 ± 2.5	0.049
Concomitant surgery			
Surgical ablation	117 (41.1%)	72 (35.6%)	0.266
<b>TV surgery</b>	<b>70 (24.6%)</b>	<b>23 (11.4%)</b>	<b>&lt;0.001</b>
others	35 (12.3%)	21 (10.4%)	0.618
<b>CPB time (mins)</b>	<b>115.0 [92.0;143.0]</b>	<b>80.0 [67.0;97.0]</b>	<b>&lt; 0.001</b>
<b>ACC time (mins)</b>	<b>77.0 [56.0;97.5]</b>	<b>53.0 [44.0;68.0]</b>	<b>&lt; 0.001</b>
Duration of ICU stay(hours)	24.0 [22.0;30.0]	24.0 [23.0;27.0]	0.459
<b>OR extubation</b>	<b>157 (55.1%)</b>	<b>182 (90.1%)</b>	<b>&lt; 0.001</b>
Re-exploration	11 ( 3.9%)	3 ( 1.5%)	0.204
Early mortality (≤ 30days)	2 ( 0.7%)	1 ( 0.5%)	0.999
Overall mortality	33 (11.6%)	14 ( 6.9%)	0.120
<b>Hospital stay (days)</b>	<b>6.0 [ 4.0; 8.0]</b>	<b>5.0 [ 4.0; 6.0]</b>	<b>&lt; 0.001</b>

# Results: perioperative data

	No NCFP (N=285)	NCFP (N=202)	P-value
Echo FU duration (months)	47.0 ± 96.1	32.0 ± 32.6	0.015
Last follow-up MR ≥ Gr 3	38 (13.3%)	10 ( 5.0%)	0.004
Survival duration (months)	85.5 ± 56.3	48.8 ± 38.4	< 0.001
Reoperation free survival	277 (97.2%)	196 (97.0%)	0.999



- The 10-year freedom from recurrent significant MR
  - no NCFP 92.6%
  - NCFP 84.7%
- The 10-year freedom from reoperation for MR
  - no NCFP 95.9%
  - NCFP 96.2%

- The simplicity of the NCFP is helpful for reducing the time of cardiopulmonary bypass and aortic cross clamp, probably proceeding short duration of hospital stay.
- In our experience, the NCFP has durability and reliability in minimally invasive mitral valve repair.